Top Stories
-
New combination chemotherapies have improved survival for patients with pancreatic cancer, and oncologist Gulam Manji sees early signs that new treatments in trials may be even better.
-
Columbia researchers have identified a gene signature in localized prostate cancer that predicts the cancer’s odds of spreading and its response to a common treatment for advanced disease.
Topic
-
Immunotherapy, often ineffective against stomach cancer, was more effective when combined with chemotherapy and given earlier, finds a new study in mice.
Topic
-
Adam Bass, MD, will join the Herbert Irving Comprehensive Cancer Center as founding director of the Center for Precision Cancer Medicine and director of gastrointestinal oncology.
Topic
Latest News
- August 30, 2017
Prakash Satwani, MD, leads NYP/CUMC's program in CAR-T therapy, a new treatment that uses a patient's own T cells to attack cancer.
Topic
- July 11, 2017
Inna Kleyman, MD, shares why she joined Velocity, a new cycling event that benefits the Herbert Irving Comprehensive Cancer Center at CUMC.
Topic
- July 11, 2017
Ilene Anesini shares why she joined Velocity, a new cycling event that benefits the Herbert Irving Comprehensive Cancer Center at CUMC.
Topic
- July 11, 2017
Alexander Small, MD, shares why he joined Velocity, a new cycling event that benefits the Herbert Irving Comprehensive Cancer Center at CUMC.
Topic
- July 10, 2017
Velocity is a new cycling event that benefits the Herbert Irving Comprehensive Cancer Center at CUMC. Columbia riders share why they joined the cause.
Topic
- May 4, 2017
Researchers discovered a mechanism that reprograms tumor cells in patients with advanced prostate cancer, reducing their response to anti-androgen therapy.
Topic
- April 6, 2017
Columbia University scientists study tumor revertants as possible new approach to cancer therapy.
Topic
- March 28, 2017
Based on new evidence, laparoscopic surgery should be offered to most women with early-stage endometrial cancer, says Columbia’s gynecologic cancer chief.
Topic
- March 27, 2017
A public-private research effort aims to develop more accurate ways of tracking a patient’s response to cancer therapy.
Topic
- March 7, 2017
The drug, developed by Columbia and MSK researchers, selectively kills cancer cells and has shown activity against multiple malignancies in pre-clinical studies.
